Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma

Who May Qualify: - Patients must have provided a signed, dated and written consent prior to any specific procedures, sampling and analyses - Patients with valide Health Inssurance Scheme - Female between 18 and 37 years old and male between 18 and 45 years old - During the 2 months before the introduction of an approved regimen of adjuvant anti-PD-1 immunotherapy or neoadjuvant plus adjuvant or targeted therapy for an high-risk of reccurence melanoma - Adjuvant or neoadjuvant plus adjuvant treatment must be prescribed as part of routine care Who Should NOT Join This Trial: - Individuals deprived of liberty or placed under the authority of a tutor - Patients unable to understand, read and/or sign an willing to sign a consent form - History of cytotoxic treatment before T0 that can alterate the studied parameters - In male, totale motile sperm count per ejaculate inferior to 39 millions at T0 - In women, an age-specific AMH level inferior to the 10th percentile at T0 - Any condition which in the Investigator's opinion would jeopardize compliance with the protocol of the study - Patients that will received an investigational treatment during the study timeframe (an observational research is allowed) - Patients who have changed the type of adjuvant treatment during adjuvant treatment (targeted switch therapy versus targeted immunotherapy and vice versa) or after the neoadjuvant phase due to the pathological response obtained. Always talk to your doctor about whether this trial is right for you.